-
51دورية أكاديمية
المؤلفون: Claus, Juana, Doesschate, Thijs ten, Gumbs, Cheyenne, van Werkhoven, Cornelis H., van der Vaart, Thomas W., Janssen, Axel B., Smits, Gaby, van Binnendijk, Rob, van der Klis, Fiona, van Baarle, Debbie, Paganelli, Fernanda L., Leavis, Helen, Verhagen, Lilly M., Joosten, Simone A., Bonten, Marc J.M., Netea, Mihai G., van de Wijgert, Janneke H.H.M.
المصدر: BCG-Corona Study Group , Claus , J , Doesschate , T T , Gumbs , C , van Werkhoven , C H , van der Vaart , T W , Janssen , A B , Smits , G , van Binnendijk , R , van der Klis , F , van Baarle , D , Paganelli , F L , Leavis , H , Verhagen , L M , Joosten , S A , Bonten , M J M , Netea , M G & van de Wijgert , J H H M 2023 , ' BCG Vaccination of ....
مصطلحات موضوعية: Bacillus Calmette-Guerin vaccine, COVID-19, health care workers, randomized placebo-controlled clinical trial, SARS-CoV-2
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1128/mbio.00356-23Test
https://hdl.handle.net/11370/0d3a49ba-cb28-4a59-a114-9d5dfc4abd0fTest
https://research.rug.nl/en/publications/0d3a49ba-cb28-4a59-a114-9d5dfc4abd0fTest
https://pure.rug.nl/ws/files/702749034/mbio.00356-23.pdfTest -
52دورية أكاديمية
المؤلفون: Barratt, Jonathan, Rovin, Brad, Wong, Muh Geot, Alpers, Charles E., Bieler, Stewart, He, Ping, Inrig, Jula, Komers, Radko, Heerspink, Hiddo J.L., Mercer, Alex, Noronha, Irene L., Radhakrishnan, Jai, Rheault, Michelle N., Rote, William, Trachtman, Howard, Trimarchi, Hernán, Perkovic, Vlado
المصدر: PROTECT investigators , Barratt , J , Rovin , B , Wong , M G , Alpers , C E , Bieler , S , He , P , Inrig , J , Komers , R , Heerspink , H J L , Mercer , A , Noronha , I L , Radhakrishnan , J , Rheault , M N , Rote , W , Trachtman , H , Trimarchi , H & Perkovic , V 2023 , ' IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study ' , Kidney International Reports , vol. 8 , no. ....
مصطلحات موضوعية: dual endothelin angiotensin receptor antagonist, ethnicity, immunoglobulin A nephropathy, race, randomized controlled clinical trial, sparsentan
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1016/j.ekir.2023.02.1086Test
https://hdl.handle.net/11370/ef3e5c08-fad1-4a70-8ddd-9ee4c56a73d5Test
https://research.rug.nl/en/publications/ef3e5c08-fad1-4a70-8ddd-9ee4c56a73d5Test
https://pure.rug.nl/ws/files/667840975/IgA_Nephropathy_Patient_Baseline_Characteristics_in_the_Sparsentan_PROTECT_Study.pdfTest -
53دورية أكاديمية
المؤلفون: Vinke, Joanna Sophia J., Altulea, Dania H.A., Eisenga, Michele F., Jagersma, Renate L., Niekolaas, Tessa M., van Baarle, Debbie, Heiden, Marieke van Der, Steenhuis, Maurice, Rispens, Theo, Abdulahad, Wayel H., Sanders, Jan Stephan F., De Borst, Martin H.
المصدر: Vinke , J S J , Altulea , D H A , Eisenga , M F , Jagersma , R L , Niekolaas , T M , van Baarle , D , Heiden , M V D , Steenhuis , M , Rispens , T , Abdulahad , W H , Sanders , J S F & De Borst , M H 2023 , ' Ferric carboxymaltose and SARS-CoV-2 vaccination-induced immunogenicity in kidney transplant recipients with iron deficiency : The COVAC-EFFECT randomized controlled trial ' , Frontiers in Immunology , vol. 13 , 1017178 . https://doi.org/10.3389/fimmu.2022.1017178Test
مصطلحات موضوعية: iron deficiency, kidney transplantation, randomized controlled (clinical) trial, SARS-CoV-2, vaccination
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.3389/fimmu.2022.1017178Test
https://hdl.handle.net/11370/1e08379e-0d1b-4291-8548-0e5251ecb323Test
https://research.rug.nl/en/publications/1e08379e-0d1b-4291-8548-0e5251ecb323Test
https://pure.rug.nl/ws/files/589196958/fimmu_13_1017178.pdfTest -
54دورية أكاديمية
المصدر: Slot , W , Raghoebar , G M , Cune , M S , Vissink , A & Meijer , H J A 2023 , ' Maxillary overdentures supported by four or six implants in the anterior region : 10-year randomized controlled trial results ' , Journal of Clinical Periodontology , vol. 50 , no. 1 . https://doi.org/10.1111/jcpe.13726Test
مصطلحات موضوعية: dental implants, edentulous, maxilla, overdenture, randomized controlled clinical trial
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1111/jcpe.13726Test
https://hdl.handle.net/11370/b2c8d02f-abc6-4564-9898-013610a5ef6fTest
https://research.rug.nl/en/publications/b2c8d02f-abc6-4564-9898-013610a5ef6fTest
https://pure.rug.nl/ws/files/251127597/J_Clinic_Periodontology_2022_Slot_Maxillary_overdentures_supported_by_four_or_six_implants_in_the_anterior_region_.pdfTest -
55دورية أكاديمية
المؤلفون: Sung, Valerie, Ching, Teresa Y. C., Smith, Libby, Marnane, Vivienne, Saetre-Turner, Michelle, King, Alison, Beswick, Rachael, Iseli, Claire E., Carew, Peter
المصدر: Sung , V , Ching , T Y C , Smith , L , Marnane , V , Saetre-Turner , M , King , A , Beswick , R , Iseli , C E & Carew , P 2023 , ' Mild matters : trial learnings and importance of community engagement in research for early identified bilateral mild hearing loss ' , Frontiers in pediatrics , vol. 11 , 1197739 , pp. 1-13 . https://doi.org/10.3389/fped.2023.1197739Test
مصطلحات موضوعية: acceptability and feasibility, hearing amplification, newborn hearing screening, pediatric mild bilateral hearing loss, randomized controlled clinical trial (RCT)
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.3389/fped.2023.1197739Test
https://researchers.mq.edu.au/en/publications/a510af12-87bd-4736-993b-c80cd273cc70Test
https://research-management.mq.edu.au/ws/files/290225680/290222508.pdfTest
http://www.scopus.com/inward/record.url?scp=85168516896&partnerID=8YFLogxKTest -
56دورية أكاديمية
المؤلفون: Mohamed El-Tanani, Khaled Abdul-Aziz Ahmed, Ashok K. Shakya, Wesam G. Ammari, Abdel-Elah Al-Shudifat
المصدر: Pharmaceuticals; Volume 16; Issue 6; Pages: 799
مصطلحات موضوعية: placebo-controlled clinical trial, mebendazole, COVID-19 outpatients, repurposing
وصف الملف: application/pdf
العلاقة: Pharmacology; https://dx.doi.org/10.3390/ph16060799Test
-
57دورية أكاديمية
المؤلفون: G. A. Serebrennikov, К. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, I. A. Menshikova, N. I. Sultanbaeva, D. O. Lipatov, A. Sh. Rezyapova, Г. А. Серебренников, К. В. Меньшиков, А. В. Султанбаев, Ш. И. Мусин, И. А. Меньшикова, Н. И. Султанбаева, Д. О. Липатов, А. Ш. Резяпова
المساهمون: This work is not funded, Данная работа не финансировалась
المصدر: Creative surgery and oncology; Том 13, № 2 (2023); 131-142 ; Креативная хирургия и онкология; Том 13, № 2 (2023); 131-142 ; 2076-3093 ; 2307-0501
مصطلحات موضوعية: ингибиторы иммунных контрольных точек, liver neoplasms, clinical practice, atezolizumab, bevacizumab, clinical trials, randomized controlled clinical trial, immune checkpoint inhibitors, новообразования печени, клиническая практика, атезолизумаб, бевацизумаб, клинические исследования, рандомизированное контролируемое клиническое исследование
وصف الملف: application/pdf
العلاقة: https://www.surgonco.ru/jour/article/view/810/547Test; Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019; 380 (15): 1450–62. DOI:10.1056/NEJMra1713263; Ахметгареева К. Т., Липатов О. Н., Меньшиков К. В., Султанбаев А. В. Заболеваемость первичным раком печени в Республике Башкортостан. В кн.: Белые ночи 2020 : тезисы VI Петербургского международного онкологического форума. СПб; 2020. С. 22.; Xie Y. Hepatitis B virus-associated hepatocellular carcinoma. Adv Exp Med Biol. 2017; 1018: 11–21. DOI:10.1007/978-981-10-5765-6_2; Kanwal F., Kramer J. R., Mapakshi S., Natarajan Y., Chayanupatkul M., Richardson P. A., et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018; 155 (6): 1828–37.e2. DOI:10.1053/j.gastro.2018.08.024; Меньшиков К. В., Султанбаев А. В., Мусин Ш. И., Рахматуллина И. Р., Меньшикова И. А., Абдеев Р. Р. и др. Гепатоцеллюлярная карцинома: этиологические факторы и механизмы развития. Обзор литературы. Креативная хирургия и онкология. 2022; 12 (2): 139–50. DOI:10.24060/2076-3093-2022-12-2-139-150; Llovet J. M., Villanueva A., Lachenmayer A., Finn R. S. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015; 12 (7): 408–24. DOI:10.1038/nrclinonc.2015.103; Cheng A. L., Kang Y. K., Chen Z., Tsao C. J., Qin S., Kim J. S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol. 2009; 10 (1): 25–34. DOI:10.1016/S1470-2045(08)70285-7; Llovet J. M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J. F., et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359 (4): 378–90. DOI:10.1056/NEJMoa0708857; Меньшиков К. В., Султанбаев А. В., Мусин Ш. И., Меньшикова И. A., Абдеев Р. Р., Султанбаева Н. И. и др. Иммунотерапия распространенной гепатоцеллюлярной карциномы : обзор литературы и клинический случай. Медицинский совет. 2022; 16 (9): 31–9. DOI:10.21518/2079-701X-2022-16-9-31-39; Kudo M., Finn R. S., Qin S., Han K. H., Ikeda K., Piscaglia F., et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391 (10126): 1163–73. DOI:10.1016/S0140-6736(18)30207-1; Bruix J., Qin S., Merle P., Granito A., Huang Y. H., Bodoky G., et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389 (10064): 56–66. DOI:10.1016/S0140-6736(16)32453-9; Меньшиков К. В., Султанбаев А. В., Ахметгареева К. Т., Липатов Д. О. Лечение метастатического гепатоцеллюлярного рака ленватинибом. Клинический случай и обзор литературы. Современная онкология. 2021; 23 (1): 156–61. DOI:10.26442/18151434.2021.1.200785; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69 (1): 182–236. DOI:10.1016/j.jhep.2018.03.019; Heimbach J. K., Kulik L. M., Finn R. S., Sirlin C. B., Abecassis M. M., Roberts L. R., et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; 67 (1): 358–80. DOI:10.1002/hep.29086; Matsui J., Yamamoto Y., Funahashi Y., Tsuruoka A., Watanabe T., Wakabayashi T., et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008; 122 (3): 664–71. DOI:10.1002/ijc.23131; Tamai T., Hayato S., Hojo S., Suzuki T., Okusaka T., Ikeda K., et al. Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol. 2017; 57 (9): 1138–47. DOI:10.1002/jcph.917; Finn R. S., Ikeda M., Zhu A. X., Sung M. W., Baron A. D., Kudo M., et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020; 38 (26): 2960–70. DOI:10.1200/JCO.20.00808; Pishvaian M. J., Lee M. S., Ryoo B.-Y., Stein S., Lee K-H., Verret W., et al. Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Ann Oncol. 2018; 29 (Suppl.8): 718–9.; Finn R. S., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T. Y., et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382 (20): 1894–905. DOI:10.1056/NEJMoa1915745; Giannini E. G., Aglitti A., Borzio M., Gambato M., Guarino M., Iavarone M., et al. Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and The ITA.LI.CA Cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. Cancers (Basel). 2019;11(11):1689. DOI:10.3390/cancers11111689; Gordan J. D., Kennedy E. B., Abou-Alfa G. K., Beg M. S., Brower S. T., Gade T. P., et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO Guideline. J Clin Oncol. 2020; 38 (36): 4317–45. DOI:10.1200/JCO.20.02672; de Castro T., Jochheim L. S., Bathon M., Welland S., Scheiner B., Shmanko K., et al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol. 2022; 14: 17588359221080298. DOI:10.1177/17588359221080298; Hatanaka T., Kakizaki S., Hiraoka A., Tada T., Hirooka M., Kariyama K., et al. Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study. Cancer Med. 2023; 12 (5): 5293–303. DOI:10.1002/cam4.5337; Shimose S., Hiraoka A., Nakano M., Iwamoto H., Tanaka M., Tanaka T., et al. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. Cancer Med. 2021; 10 (23): 8530–41. DOI:10.1002/cam4.4367; Hatanaka T., Kakizaki S., Nagashima T., Namikawa M., Ueno T., Tojima H., et al. Lenvatinib for hepatocellular carcinoma patients with nonviral infection who were unlikely to respond to immunotherapy: a retrospective, comparative study. Oncology. 2021; 99 (10): 641–51. DOI:10.1159/000517494; Tsuchiya K., Kurosaki M., Sakamoto A., Marusawa H., Kojima Y., Hasebe C., et al. The real-world data in japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study. Cancers (Basel). 2021; 13 (11): 2608. DOI:10.3390/cancers13112608; Hiraoka A., Kumada T., Tada T., Tani J., Kariyama K., Fukunishi S., et al. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Sci Rep. 2021; 11 (1): 16663. DOI:10.1038/s41598-021-96089-x; Tomonari T., Sato Y., Tanaka H., Mitsuhashi T., Hirao A., Tanaka T., et al. Th erapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. JGH Open. 2021; 5 (11): 1275–83. DOI:10.1002/jgh3.12663; Pugh R. N., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60 (8): 646–9. DOI:10.1002/bjs.1800600817; Tada T., Kumada T., Hiraoka A., Hirooka M., Kariyama K., Tani J., et al. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Med. 2022; 11 (20): 3796–808. DOI:10.1002/cam4.4763; Singal A. G., Lampertico P., Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020; 72 (2): 250–61. DOI:10.1016/j.jhep.2019.08.025; Global Burden of Disease Liver Cancer Collaboration; Akinyemiju T., Abera S., Ahmed M., Alam N., Alemayohu M. A., Allen C., et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017; 3 (12): 1683–91. DOI:10.1001/jamaoncol.2017.3055; Kumada T., Toyoda H., Tada T., Yasuda S., Tanaka J. Changes in background liver function in patients with hepatocellular carcinoma over 30 years: comparison of child-pugh classification and albumin bilirubin grade. Liver Cancer. 2020; 9 (5): 518–28. DOI:10.1159/000507933; Johnson P. J., Berhane S., Kagebayashi C., Satomura S., Teng M., Reeves H. L., et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015; 33 (6): 550–8. DOI:10.1200/JCO.2014.57.9151; Iwamoto H., Shimose S., Noda Y., Shirono T., Niizeki T., Nakano M., et al. Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real-world clinical practice. Cancers (Basel). 2021; 13 (11): 2786. DOI:10.3390/cancers13112786; Finn R. S., Ryoo B. Y., Merle P., Kudo M., Bouattour M., Lim H. Y., et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020; 38 (3): 193–202. DOI:10.1200/JCO.19.01307; Yau T., Park J. W., Finn R. S., Cheng A. L., Mathurin P., Edeline J., et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022; 23 (1): 77–90. DOI:10.1016/S1470-2045(21)00604-5; Cheng A. L., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T. Y., et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022; 76 (4): 862–73. DOI:10.1016/j.jhep.2021.11.030; Finn R. S., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T.-Y., et al. IMbrave150: Updated Overall Survival (OS) Data from a Global, Randomized, Open-Label Phase III Study of Atezolizumab (Atezo) + Bevacizumab (Bev) versus Sorafenib (Sor) in Patients (Pts) with Unresectable Hepatocellular Carcinoma (HCC). J Clin Oncol. 2021; 39 (3S): 267. DOI:10.1200/JCO.2021.39.3_suppl.267; Galle P. R., Finn R. S., Qin S., Ikeda M., Zhu A. X., Kim T. Y., et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22 (7): 991–1001. DOI:10.1016/S1470-2045(21)00151-0; Eisenhauer E. A., Therasse P., Bogaerts J., Schwartz L. H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45 (2): 228–47. DOI:10.1016/j.ejca.2008.10.026; Lencioni R., Llovet J. M. Modifi ed RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30 (1): 52–60. DOI:10.1055/s-0030-1247132; Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Bethesda; 2009.; Common Terminology Criteria for Adverse Events (CTCAE). v.5.0; Cancer Therapy Evaluation Program (CTEP). Rockville; 2017.; Himmelsbach V., Pinter M., Scheiner B., Venerito M., Sinner F., Zimpel C., et al. Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: experience from four tertiary centers. Cancers (Basel). 2022; 14 (7): 1722. DOI:10.3390/cancers14071722; Qin S., Ren Z., Feng Y. H., Yau T., Wang B., Zhao H., et al. Atezolizumab plus bevacizumab versus sorafenib in the chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study. Liver Cancer. 2021; 10 (4): 296–308. DOI:10.1159/000513486; Pfister D., Núñez N. G., Pinyol R., Govaere O., Pinter M., Szydlowska M., et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021; 592 (7854): 450–6. DOI:10.1038/s41586-021-03362-0; Inada Y., Mizukoshi E., Seike T., Tamai T., Iida N., Kitahara M., et al. Characteristics of immune response to tumor-associated antigens and immune cell profile in patients with hepatocellular carcinoma. Hepatology. 2019; 69 (2): 653–65. DOI:10.1002/hep.30212; https://www.surgonco.ru/jour/article/view/810Test
الإتاحة: https://doi.org/10.24060/2076-3093-2023-13-2-131-142Test
https://doi.org/10.1056/NEJMra1713263Test
https://doi.org/10.1007/978-981-10-5765-6_2Test
https://doi.org/10.1053/j.gastro.2018.08.024Test
https://doi.org/10.24060/2076-3093-2022-12-2-139-150Test
https://doi.org/10.1038/nrclinonc.2015.103Test
https://doi.org/10.1016/S1470-2045Test(08)70285-7
https://doi.org/10.1056/NEJMoa0708857Test
https://doi.org/10.21518/2079-701X-2022-16-9-31-39Test
https://doi.org/10.1016/S0140-6736Test(18)30207-1 -
58دورية أكاديمية
المؤلفون: Heerspink, Hiddo L, Jongs, Niels, Neuen, Brendon, Schloemer, Patrick, Vaduganathan, Muthiah, Inker, Lesley, Fletcher, Robert A, Wheeler, David C, Bakris, George, Greene, Tom, Chertow, Glenn M, Perkovic, Vlado
المصدر: Kidney International , 104 (1) pp. 181-188. (2023)
مصطلحات موضوعية: Kidney Failure, MineraloCorticoid Receptor Antagonist, Randomized Controlled Clinical Trial, SGLT2 inhibitor
وصف الملف: text
العلاقة: https://discovery.ucl.ac.uk/id/eprint/10169474/7/Wheeler_PIIS0085253823003095.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10169474Test/
-
59دورية أكاديمية
المؤلفون: Delphine Teigné, Anne-Sophie Banaszuk, Charlotte Grimault, Linda Abes, Aurélie Gaultier, Cédric Rat
المصدر: Frontiers in Public Health, Vol 10 (2022)
مصطلحات موضوعية: screening uptake, cervical cancer screening (CCS), organized screening programmes, general practitioners, randomized controlled clinical trial (RCT), Public aspects of medicine, RA1-1270
وصف الملف: electronic resource
العلاقة: https://www.frontiersin.org/articles/10.3389/fpubh.2022.1035288/fullTest; https://doaj.org/toc/2296-2565Test
-
60دورية أكاديمية
المؤلفون: Jia-Ni Li, Chen-Chen Xie, Chang-Qing Li, Gui-Fang Zhang, Hao Tang, Chuan-Na Jin, Jing-Xi Ma, Lan Wen, Ke-Ming Zhang, Ling-Chuan Niu
المصدر: Neural Regeneration Research, Vol 17, Iss 8, Pp 1809-1813 (2022)
مصطلحات موضوعية: activity of daily living, early stage treatment, emotional disorder, limb dysfunction, neural regeneration, randomized controlled clinical trial, rehabilitation, safety of treatment, stroke, transcutaneous auricular-vagus nerve stimulation, Neurology. Diseases of the nervous system, RC346-429
وصف الملف: electronic resource
العلاقة: http://www.nrronline.org/article.asp?issn=1673-5374;year=2022;volume=17;issue=8;spage=1809;epage=1813;aulast=LiTest; https://doaj.org/toc/1673-5374Test
النص الكامل